Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neutropenia 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Infections 1Carcinoma, Hepatocellular 1

Interventions

Voriconazole 4Vancomycin 3Fluconazole 3Filgrastim 3Ciprofloxacin 3Caspofungin 3liposomal amphotericin B 2Trimethoprim, Sulfamethoxazole Drug Combination 2Therapeutics 2Piperacillin, Tazobactam Drug Combination 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Itraconazole 2Granulocyte Colony-Stimulating Factor 2Fosfomycin 2Daptomycin 2Cyclophosphamide 2Cefazolin 2Antibiotic Prophylaxis 2ziprasidone 1threonic acid 1telavancin 1soybean oil, phospholipid emulsion 1plerixafor 1monalizumab 1lime 1human papillomavirus vaccine, L1 type 16, 18 1fluorescein isothiocyanate-keyhole limpet hemocyanin 1fludarabine phosphate 1fish oil triglycerides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Infections × Anidulafungin × Clear all
NCT00068471 2013-06-19

Anidulafungin in Treating Immunocompromised Children With Neutropenia

National Cancer Institute (NCI)

Phase 1/2 Completed

Infections, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡